Venlafaxine extended release versus conventional antidepressants in the remission of depressive disorders after previous antidepressant failure: ARGOS study

Baldomero, Enrique Baca; Ubago, José Giner; Cercós, Carmen Leal; Ruiloba, Julio Vallejo; Calvo, C. García; Lopez, Rieza

doi:10.1002/da.20080

Cited by 66 publications

(34 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Unfortunately, the number of high-quality studies that investigated this issue is relatively small. The STAR*D [32] and the European ARGOS [33] trials have focused on this question, as have a limited number of RCTs.…”

Section: Resultsmentioning

confidence: 99%

The Integrative Management of Treatment-Resistant Depression: A Comprehensive Review and Perspectives

Carvalho

Berk

Hyphantis

et al. 2014

Psychother Psychosom

102

View full text Add to dashboard Cite

Background: Major depressive disorder is a prevalent and disabling illness. Notwithstanding numerous advances in the pharmacological treatment of depression, approximately 70% of patients do not remit after first-line antidepressant treatment. Methods: The MEDLINE/PubMed, EMBASE and ClinicalTrials.gov electronic databases were searched from inception to October 1, 2013, for randomized controlled trials (RCT), relevant open-label trials, meta-analyses and ongoing trials of pharmacological and psychotherapeutic approaches to treatment-resistant depression (TRD). Results: Switching to a different antidepressant is a useful option following nonresponse to a first-line agent. Although widely used in clinical practice, there is limited evidence to support antidepressant combination for TRD. Notwithstanding evidence for lithium or T₃ augmentation to be successful in TRD, most studies were carried out when participants were treated with tricyclic antidepressants (TCA). Of the available strategies to augment the response to new-generation antidepressants, the use of some atypical antipsychotics is best supported by evidence. Several novel therapeutic options are currently discussed. Evidence suggests that cognitive therapy (CT) is an effective strategy for TRD. Conclusions: The success of switching to a different antidepressant following a first-line agent is supported by evidence, but there is limited evidence for effective combination strategies. Lithium and T₃ augmentation of TCA have the strongest evidence base for successful treatment of TRD. The use of augmentation of newer-generation antidepressants with atypical antipsychotics is supported by a growing evidence base. Current evidence supports CT as an effective strategy for TRD. There is a need for additional large-scale RCT of TRD. The development of new antidepressants targeting novel pathways opens a promising perspective for the management of TRD.

show abstract

Section: Resultsmentioning

confidence: 99%

The Integrative Management of Treatment-Resistant Depression: A Comprehensive Review and Perspectives

Carvalho

Berk

Hyphantis

et al. 2014

Psychother Psychosom

102

View full text Add to dashboard Cite

show abstract

“…Using 3 randomized clinical trials (RCTs), including STAR*D, 12,14,15 Ruhe et al performed a systematic review. 16 Pooled results from 8 RCTs and 23 open-label studies showed a modest and "clinically equivocally advantageous" increased remission rate for venlafaxine over SSRIs (number needed to treat = 13 [95% confidence interval (CI) = 9.1-25.0]).…”

mentioning

confidence: 99%

Pharmacy and Medical Costs Associated With Switching Between Venlafaxine and SSRI Antidepressant Therapy for the Treatment of Major Depressive Disorder

Khandker¹,

Kruzikas²,

McLaughlin³

2008

JMCP

View full text Add to dashboard Cite

BACKGROUND: While much has been published on utilization of anti depressants and associated resource use, surprisingly little information is available on the relationship between a change in antidepressant agent and health care utilization. Given that many patients will not respond to initial therapy (and therefore would be candidates for switching treatment) and the array of antidepressant medications on the market, information on the impact of switching would be beneficial to both providers and policymakers.OBJECTIVE: To explore patterns of antidepressant drug use and depression related and allcause medical costs for patients who switched therapy between 2 drug classes, selective serotonin reuptake inhibitors (SSRIs) and the selective norepinephrine reuptake inhibitor (SNRI) venlafaxine.METHODS: Using an administrative claims database of 36 million members from 61 health plans, this retrospective cohort analysis examined patients who had (1) a diagnosis of major depressive disorder (MDD, International Classification of Diseases, Ninth Revision, Clinical Modification [ICD9CM] code 296.2x for MDD single episode, 296.3x for MDD recurrent episode, 300.4 for dysthymic disorder, and 311 for depressive disorder not else where classified) and (2) a newly prescribed antidepressant during the year 2002. Costs were defined as amounts paid by health plans for all inpatient, outpatient, physician and pharmacy services (i.e., allowed charges after subtraction of member costshare). Depressionrelated costs were defined using (1) medical claims with primary diagnosis of depression and (2) pharmacy claims for antidepressants. Using an index date of the first antidepressant claim, 12 months of preindex and post index data were available for all eligible patients. Switching was defined as occurring between the SSRIs and venlafaxine (i.e., patients who switched within the SSRI drug class across different SSRIs were treated as non switchers until they switched to venlafaxine), and there was no minimum or maximum gap in therapy. The SSRIs included fluoxetine, citalopram, sertraline, and paroxetine; the only SNRI on the market at the time was venlafaxine. Multivariate regression analyses determined predictors of switching and factors influencing overall and depressionrelated costs, while controlling for confounding factors. For the 12month period following the index date (fixed length of followup), the study compared perpatient peryear (PPPY) costs for (1) patients who switched versus those who did not switch and (2) patients with single versus multiple trials of SSRI for the subgroup of patients who switched from an SSRI to venlafaxine. For the time periods before versus after the switch (variable lengths of followup), perpatient means and medians of monthly cost averages (with followup periods < 1 month set to 1 month for 16.5% After adjustment for multiple covariates including demographic characteristics, 10 selected comorbidities, and physician specialty, general linear models with log transformed costs as the dependent...

show abstract

“…62 Several other studies werea lso available for citalopram and escitalopram, 63 fluoxetine and sertraline, 64 and venlafaxine. [65][66][67][68][69] Because these studies did not necessarily report sufficient information to adjust both remission and response rates, an assumption was made that the results werec onsistent for both remission and response.…”

Section: Clinical Evidencementioning

confidence: 99%

Treatment of Major Depressive Disorder in Patients Failing Initial Therapy: An Excel-Based Pharmacoeconomic Model

Malone¹,

Tierney²

2007

JMCP

View full text Add to dashboard Cite

Venlafaxine extended release versus conventional antidepressants in the remission of depressive disorders after previous antidepressant failure: ARGOS study

Cited by 66 publications

References 35 publications

The Integrative Management of Treatment-Resistant Depression: A Comprehensive Review and Perspectives

The Integrative Management of Treatment-Resistant Depression: A Comprehensive Review and Perspectives

Pharmacy and Medical Costs Associated With Switching Between Venlafaxine and SSRI Antidepressant Therapy for the Treatment of Major Depressive Disorder

Treatment of Major Depressive Disorder in Patients Failing Initial Therapy: An Excel-Based Pharmacoeconomic Model

Contact Info

Product

Resources

About